Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
Elisabeth Livingstone(German Cancer Research Center), Dirk Schadendorf(National Center for Tumor Diseases), Christine Windemuth-Kieselbach(Statistisches Bundesamt), Jochen Utikal(German Cancer Research Center), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Anja Gesierich(University of Michigan), Alexander Roesch(Essen University Hospital), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Željko Mijušković(Military Medical Academy), Friedegund Meier(National Center for Tumor Diseases), Sabine Eckhardt(NILU), Thomas Eigentler(University Children's Hospital Tübingen), Selma Ugurel(Klinikum Bielefeld), Dimitrios C. Ziogas(National and Kapodistrian University of Athens), Jean‐Jacques Grob(Aix-Marseille Université), Marlene Garzarolli, Lisa Zimmer(The University of Sydney), Lidija Kandolf Sekulović(Military Medical Academy), Mirjana Ziemer(University Medical Center), Felix Kiecker(Humboldt-Universität zu Berlin), Claus Garbe(University of Tübingen), Helen Gogas(National and Kapodistrian University of Athens), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 15
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k